Enterprise Value
1.257B
Cash
319.7M
Avg Qtr Burn
-52.73M
Short % of Float
19.01%
Insider Ownership
2.44%
Institutional Own.
97.12%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DAXXIFY (DaxibotulinumtoxinA) Details Pain, Muscle pain | Approved Quarterly sales | |
DAXXIFY (DaxibotulinumtoxinA) (injection) Details Glabellar lines | Approved Quarterly sales | |
DAXXIFY (DaxibotulinumtoxinA) Details Spasticity, Muscle control disorder, Congenital adrenal hyperplasia | Phase 3 Update | |
DaxibotulinumtoxinA Details Inflammatory disease, Heel Pain | Failed Discontinued |